Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 2.0 million shares at $105.75 per share. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 300,000 additional shares of common stock. If the underwriters exercise this option, Synageva will have offered 2.30 million shares of its common stock.
Goldman, Sachs & Co., J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC are serving as book-running managers for the offering. Cowen and Company, LLC, Canaccord Genuity Inc., Robert W. Baird & Co. Inc., and Nomura Securities International, Inc. are serving as co-managers for the offering.
The securities described above are being offered by Synageva pursuant to a Form S-3 shelf registration statement (including a base prospectus) previously filed with the Securities and Exchange Commission (SEC). Before you invest, you should read the prospectus in the registration statement and related prospectus supplement that Synageva has filed with the SEC for more complete information about Synageva and this offering. The preliminary prospectus supplement is available for free by visiting EDGAR on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained from the offices of Goldman, Sachs & Co.; by mail, Attn: Prospectus Department, 200 West Street, New York, NY 10282; by facsimile: 212-902-9316; by email: firstname.lastname@example.org; or by telephone: 866-471-2526; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone: 866-803-9204; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone: 866-718-1649 or by email: email@example.com.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.